Answers are grounded in this paper and cite their sources.
Analysis shows inversion of HLA-DPB1 mismatch hazard ratio in transplantation, highlighting a therapeutic mechanism.
Examines the sign inversion of HLA-DPB1 mismatch hazard ratio from HR=1.50 (harmful) to HR=0.62 (protective) under post-transplantation cyclophosphamide (PTCy). Argues this represents a coupling regime boundary transition — a distinct therapeutic mechanism class fundamentally different from single-target pharmacological models. Extends the framework to any therapeutic domain where outcome variables can change sign across intervention regimes.
No takes yet. Share an insight, caveat, or question.
James E. Dunn (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: